Sigma (ASX:SIG) share price slides 7% to yearly low on guidance update

An earnings downgrade has sent the company's share price deeply into the red today.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Sigma Healthcare Ltd (ASX: SIG) share price is plunging today after the company predicted its earnings will fall this financial year.

The Sigma share price is currently down by 6.67%, trading hands at 49 cents a piece. This is a 52-week low for the company.

Sigma is a pharmacy chain operator and distributor with a network of more than 1,200 pharmacies including well-known brands Chemist King, Amcal and Discount Drug Stores.

A man in a white coat holds a laptop in one hand and his head in the other, it's bad news.

Image source: Getty Images

What did Sigma announce?

In today's release, Sigma predicted its earnings before interest, taxes, depreciation, and amortisation (EBITDA) would drop by 10% in FY22.

The company downgraded its earnings forecast because of impacted sales and operating costs due to a major software update and COVID-19 restrictions. The company implemented a new enterprise resource planning system during the height of pandemic restrictions.

Sigma expects one-off and non-operating costs to be up $25 to $30 million, also proportionally impacting debt.

But while the prediction for FY22 is negative, the company reported 5% growth in September.

And the company also has a positive outlook on future growth overall.

Chairman Ray Gunston said:

Not withstanding this set-back, we remain confident in the future growth profile for Sigma, which was further underlined with the Sigma board recently approving the extension to our new Victorian Distribution Centre in Truganina.

We remain focused on growing our core business, whilst continuing to build on business expansion opportunities across areas such as hospital services, contract logistics and medical devices and consumables…

Sigma expects to announce its FY22 results on 29 March.

Sigma share price snapshot

Over the past 12 months, Sigma shares have dropped almost 17%. The Sigma share price is down 21% year to date. It reached a yearly high of 73 cents on 8 February. At 49 cents apiece, today's price at the time of writing is a yearly low for the company.

Based on today's share price, Sigma has a market capitalisation of roughly $514 million.

The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Doctor checking patient's spine x-ray image.
Healthcare Shares

Where is the value amongst ASX healthcare shares?

These three stocks are worth monitoring.

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Telix Pharmaceuticals: FDA accepts Pixclara NDA

The FDA has accepted Telix's Pixclara NDA for imaging brain cancer.

Read more »

Six smiling health workers pose for a selfie.
Healthcare Shares

Bell Potter says this ASX healthcare stock could rise nearly 200%

The positive announcement has reinforced the broker's recommendation.

Read more »

A man rests his chin in his hands, pondering what is the answer?
Healthcare Shares

CSL shares: 3 reasons to buy and 3 reasons to sell

CSL shares have tumbled again.

Read more »

Shot of a young scientist looking stressed out while working on a computer in a lab.
Broker Notes

What's Bell Potter's updated view on CSL shares?

Will the new tariffs impact CSL according to Bell Potter?

Read more »

Beautiful young woman drinking fresh orange juice in kitchen.
Healthcare Shares

Are Cogsgate shares a buy, hold or sell after rocketing 12% higher yesterday?

This broker thinks there could be more growth to come.

Read more »

woman in lab coat conducting testing.
Healthcare Shares

Is this battered ASX biotech stock ready to rocket higher?

Brokers are upbeat and see upside of up to 125%!

Read more »

young female doctor with digital tablet looking confused.
Healthcare Shares

Why are CSL shares struggling to regain momentum?

Analysts have widely considered the shares to be oversold for some time now.

Read more »